I. FINANCING OF PRIVATE BIOTECHNOLOGY COMPANIES: $379.7M | ||||
Company | Location |
Date | Amt. (M) |
Details |
BioMimetic |
Franklin, Tenn. |
11/4/04 |
$25.7 |
The Series C financing was led by InterWest Partners; other investors included CMEA Ventures, MC Life Science Ventures, Burrill & Co., Novo A/S, Holden Capital and MB Venture Partners; Pacific Growth Equities LLC was place- ment agent |
Chimerix Inc. |
San Diego |
11/4/04 |
$11 |
New investor Frazier Healthcare Ventures led the Series C preferred stock round; founding investors Sanderling Ventures and Asset Management Co. also participated |
Ellipsis Neuro- |
Toronto |
11/8/04 |
C$6 (US$5) |
The Series A financing was led by Newport Partners and included the Canadian Medical Discoveries Fund; Transition Therapeutics Inc. also participated and gained a 17% stake in Ellipsis, with an option to increase it to 52% |
Inpharmatica |
London |
11/8/04 |
£13.9 |
The third-round financing was led by Reed Elsevier Ventures and included Abingworth, Advent, Gilde, GIMV and 3i |
JDS |
New York |
11/16/04 |
$62 |
AIG Healthcare Partners LP and Galen Partners LP led the private financing round |
Metabolex |
Hayward, Calif. |
11/20/04 |
$44 |
Alta Partners led the third closing of a Series C financing round; it raised $31M more in closings dating to August 2003; other investors included Venrock Associates, Versant Ventures, Novo A/S, Bay City Capital, KBC Bank & Insurance Group, Birchmere Ventures and VantagePoint Venture Partners |
Neosil Inc. |
South San Francisco |
11/8/04 |
$32 |
MPM Capital and Burrill & Co. led the Series A preferred stock round |
ODC Therapy |
Dallas |
11/1/04 |
$4 |
Baylor Health Care System formed the company and provided $4M in seed financing |
Procognia Ltd. |
Maidenhead, UK |
11/8/04 |
$23.5 |
Lead investor Apax Partners Funds was joined by existing investors Evergreen Partners and Koor CVC and new investor Star Ventures in the financing round |
Reata Discovery Inc. |
Dallas |
11/11/04 |
$12 |
Investing in the Series C financing were Cardinal Investment Co., Ojai Goliad, StarTech Ventures and undisclosed institutions and individuals |
Symphogen A/S |
Copenhagen, Denmark |
11/2/04 |
$25 |
Investors in the Series C financing included Essex Woodlands Health Ventures (USA), Scandinavian Life Science Venture, Novo A/S, LD Pensions and Vaekstfonden |
Synta |
Lexington, Mass. |
11/22/04 |
$80 |
Existing investors that participated in the Series D financing included Caxton Group, Galleon Group, AIG SunAmerica and Aperture Partners; new institutions and individuals also participated |
Transport |
Philadelphia |
11/22/04 |
$27 |
Carlyle Venture Partners and Quaker BioVentures Inc. co-led the Series D round; existing investors, including investors affiliated with The Hillman Co., and new investor EGS HealthCare Capital Partners also participated |
Zyentia Ltd. |
Cambridge, UK |
11/17/04+ |
£1.5 (US$2.8) | Details on the first-round funding were not disclosed |
II. MILESTONE PAYMENTS AND EQUITY INVESTMENTS FROM EXISTING CORPORATE PARTNERS: $21.25M | ||||
Company |
Partner (Country) | Amt. (M) | Triggering Event | Details (Date) |
Abgenix Inc. |
CuraGen Corp. |
ND |
Milestone payment |
Triggered by the advancement of CR002, a fully human antibody against PDGF-D created by Abgenix, into a Phase I trial, the first trial from their collaboration (11/18) |
Celgene |
Novartis Pharma AG (Switzerland) |
$7.5 |
Milestone payment |
Triggered by the FDA's acceptance for review Novartis' NDA seeking approval of Focalin XR for treating pediatric and adult attention deficit/hyperactivity disorder (10/25)** |
Cell |
Nippon Shinyaku Co. Ltd. (Japan) |
$0.5 |
Milestone payment |
Triggered by Nippon getting approval of Trisenox in Japan for treating relapsed or refractory acute promyelocytic leukemia (10/25)** |
ChondroGene |
Pfizer Inc. |
$1 |
Milestone payment |
The third and final milestone was reached in their October 2002 collaboration to identify therapeutic targets and diagnostic biomarkers for osteoarthritis (11/15) |
Galapagos |
Wyeth |
ND |
Milestone payment |
Wyeth selected a set of targets for internal development from their November 2003 collaboration in osteoporosis (11/9) |
Genelabs |
GlaxoSmithKline plc (UK) |
$0.75 |
Milestone payment |
Related to trial results for GSK's vaccine against the hepatitis E virus, which it is devel- oping under a license from Genelabs (11/11) |
Isis |
Eli Lilly and Co. |
$1.5 |
Milestone payment |
Triggered by the move into Phase I trials of the antisense cancer drug LY2181308, which was licensed to Lilly in April 2003 (11/17) |
Medarex Inc. |
Amgen Inc. |
ND |
Milestone payment |
Triggered by Amgen's advancement into clinical trials of an antibody developed using Medarex's UltiMAb technology (11/29) |
Pharmacopeia |
Schering-Plough Corp. |
ND |
Milestone payment |
Triggered by Schering-Plough's decision to nominate a cancer compound developed in their collaboration for full preclinical evalu-ation (11/30) |
Pharmacopeia |
NV Organon (the Netherlands) |
ND |
Milestone payment |
Triggered by Pharmacopeia's delivery of a development candidate under their 2002 research collaboration (11/9) |
Vertex |
Novartis AG (Switzerland) |
$10 |
Milestone payment |
Triggered by Novartis' selection of a small- molecule protein kinase inhibitor, VX-322, for clinical development for cancer, under their February 2004 amended collaboration (11/10) |
Notes: | ||||
# Unless otherwise indicated, shares are traded on the Nasdaq exchange. | ||||
* = Private company. | ||||
** = Item occurred in October but was not included in previous chart. | ||||
+ = Denotes the date the item ran in BioWorld International. | ||||
Currency conversions are based on exchange rates at the time of the deal. | ||||
ND = Not disclosed. | ||||
TSE = Toronto Stock Exchange. | ||||
